Aktis Oncology, Inc. (AKTS) vs Savara Inc. (SVRA)
Aktis Oncology, Inc. and Savara Inc. are both Biotechnology companies. Aktis Oncology, Inc. and Savara Inc. are of similar size ($1.1B and $1.0B). Savara Inc. has the higher net margin (0.00% vs −782.0%) and the lower return on invested capital (−12,213.2% vs 0.00%). Across the 14 metrics below, Aktis Oncology, Inc. leads on 7 and Savara Inc. on 7.
Valuation
Profitability
| Metric | AKTS | SVRA | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 0.00% | 65.16% |
| Operating margin | (939.13%) | 0.00% | 0.00% |
| Net margin | (781.95%) | 0.00% | 0.00% |
| Free cash flow margin | (1,442.91%) | 0.00% | 0.00% |
| Return on equity | (34.45%) | (105.48%) | (57.72%) |
| Return on assets | (27.09%) | (78.28%) | (49.22%) |
| Return on invested capital | 0.00% | (12,213.18%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack